Biotech Showcase™ 2013 Program Overview
www.ebdgroup.com/bts/program| Monday, January 7, 2013 | |||||
|---|---|---|---|---|---|
| 7:00 am | Level 4, Cyril Magnin Foyer
Registration Opens and Continental Breakfast |
||||
| 8:00–9:00 am |
Parallel Workshops
The Watch List of 2013 Monday, 8:00–9:00 am Level 3, Powell Learn what top biotech analysts think are the driving macro trends and specific opportunities for 2013 and how investors can capitalize on them. Each analyst on this all-star panel details his 2013 Watch List. You will learn:
Behind their comments is a groundbreaking report by The Life Sciences Report and Sagient Research that analyzes pharmaceutical and medical products in the pipeline today that will hit the testing and healthcare market in 2013. Moderator:
Share this: How asset-centric biotech structures can open new avenues for achieving liquidity Monday, 8:00–9:00 am Level 4, Mission II This workshop will provide insights into how these structures can provide opportunities for earlier liquidity for investors and favorable tax efficient structures. As the IPO and M&A path to liquidity for investors in the typical company-centric models has gotten tougher, alternative structures focusing on assets is proving attractive to both product and platform companies. In addition to the option of spinning out C corporations around assets, another approach is an LLC structure which offers the normal liquidity options, i.e., M&A or future IPO, while opening up new avenues for achieving liquidity. And this new angle on liquidity should help solve one of the biggest challenges in the venture funding of discovery platforms: long, liquid timelines where capital is locked up at flat prices. Insights from our panelists will demystify the structures and process. Examples will include companies initially formed as LLC holding companies as well as a typical C company like Adimab that later converts to an LLC structure. Moderator:
Share this: |
||||
| 9:00 am–12:00 pm | Company Presentations ►
Private Biotech |
||||
| 12:00–1:40 pm |
Lunch Plenary Deciding to go commercial in the go-it-alone era: Can we resolve the risk vs. the reward? Monday, 12:00–1:40 pm Level 4, Cyril Magnin Ballroom The path from clinical development toward commercialization is an arduous one for most any emerging pharmaceutical or biotech company. We're all familiar with the milestones and success factors that occur along the way—a combination of raising money, conducting clinical trials and pursuing potential partners. Early stage deals have become more difficult to achieve as large pharma and biotech companies continue to push risk back down the value chain to emerging companies. This leaves emerging companies with the task of continuing to raise money and conducting the next phase of clinical trials. The process continues. As assets progress into Phase IIb and into Phase III, leaders at emerging companies face a key strategic question: Do they continue to pursue deals (either licensing or M&A) with larger partners or do they take the somewhat riskier (but potentially more lucrative) approach of becoming a fully integrated pharmaceutical company with an internal commercialization capability? For many reasons, the market is "forcing the hand" of emerging biotechs, making this a more critical question that ever before. Any decision that is made may impact not only the first asset to go to market, but the resources available to advance the remaining assets in a company's portfolio. The entire company is at a crossroads. Join this panel of senior industry executives from emerging biotechs, large pharma, VC firms and investment banks as they discuss the risks and rewards of various biotech business models including the pursuit of an independent commercialization strategy. Moderator:
Share this: |
||||
| 1:45–5:15 pm | Company Presentations ►
Private Biotech |
1:30–6:00 pm One-to-one Meetings ► |
|||
| Tuesday, January 8, 2013 | |||||
|---|---|---|---|---|---|
| 7:00 am | Level 4, Cyril Magnin Foyer
Registration Opens and Continental Breakfast |
||||
| 8:00–9:00 am |
Parallel Workshops
Oncology reimbursement: Is the future now? Tuesday, 8:00–9:00 am Level 4, Mission II While access for oncology products was largely unfettered in the past, that era is ending. Not only are payers beginning to select preferred oncology agents, but they are also focusing on paying providers to adhere to guidelines, and asking providers to use certain formulations of oncology agents. What does this mean for the development and launch of new oncology agents? Come and find out! Moderator:
Share this: Where is the money? Raising capital outside of the equity markets Tuesday, 8:00–9:00 am Level 4, Mission I A choppy IPO market and decreasing pool of biotech venture capital have led companies to seek financing from alternative sources. This panel will discuss where companies are finding success in raising capital. Moderator:
Share this: eHealth: Medicine's next frontier Tuesday, 8:00–9:00 am Level 3, Powell When you walk into a doctor's office five years from now, will you be prescribed an app? Medicine has traditionally been dominated by drugs, devices, biologics and counseling. eHealth represents a new way of treating patients that could have a major impact on stakeholders in the healthcare system including doctors, patients and the pharma industry. As new technologies emerge and non-traditional players (e.g., phone companies) start to cross over into healthcare, the biotech ecosystem may look radically different in the future. This workshop will explore emerging trends in eHealth, strategies companies are pursuing and major issues that the eHealth space faces (e.g., the current and future regulatory environment). Moderator:
Share this: | 8:00 am–12:00 pm One-to-one Meetings ► |
|||
| 8:00–10:00 am |
Alliance for Regenerative Medicine
2013 Regenerative Medicine State of the Industry Briefing Tuesday, 8:00–9:00 am Level 2, Divisadero The Alliance for Regenerative Medicine's third annual State of the Industry Briefing provides an overview of recent advances in the clinic in major disease areas as well as the outlook for 2013 for the regenerative medicine and cell therapy sectors. The session's speakers include CEOs of the leading companies in the sector, executives from big pharma with responsibilities in RM, experts on induced pluripotent stem cells—the technology that was the focus of the recent Nobel Prize for medicine—and representatives from the patient advocacy communities. Presentations will also include an overview of the sector's financial performance and a discussion among industry leaders of the critical factors for success and how they will work to influence both technology development and the evolving regulatory framework. Moderator: Share this: Regenerative Medicine Analyst Outlook 2013 Tuesday, 9:00–10:00 am Level 2, Divisadero The regenerative medicine and advanced therapies sector is a diverse and rapidly growing market. This panel, featuring expert healthcare buy side and sell side analysts focusing on regenerative medicine and other advanced therapies, will discuss the outlook for the sector from the investor's perspective. They will touch on major data events and other developments they believe will influence valuations in the sector. Further, the panel with share insight on the sector's key trends; innovations and emerging technologies, and how these developments will affect strategic planning and business decisions over the course of the next 12 months. Moderator: Share this: |
||||
| 9:00 am–12:00 pm | Company Presentations ►
Private Biotech |
||||
| 12:00–1:40 pm |
Lunch Plenary Funding biotech: Do we need a superfund? Tuesday, 12:00–1:40 pm Level 4, Cyril Magnin Ballroom In March 2012, Mark Kessel wrote an op-ed for The Scientist calling for the establishment of a biotech superfund funded by pharma. In this article, Kessel outlines the capital crisis the biopharma industry faces—widely recognized in the industry—and its overall negative impact on innovation and the development of new therapies. Kessel contends that a superfund, modeled after the successful SEMATECH superfund, is a viable tool that can address the need to fund innovation for both biotech and pharma. This panel of thought leaders will share their thoughts about the capital crisis, its effect on innovation and the possibility of creating a superfund. Moderator:
Share this: |
||||
| 1:45–5:15 pm | Company Presentations ►
Private Biotech |
1:30–6:00 pm One-to-one Meetings ► |
|||
| Wednesday, January 9, 2013 | |||||
|---|---|---|---|---|---|
| 7:00 am | Level 4, Cyril Magnin Foyer
Registration Opens and Continental Breakfast |
||||
| 8:00–9:00 am |
Parallel Workshops
Obesity: A big problem. Where are we today and where are we going? Wednesday, 8:00–9:00 am Level 4, Mission II Obesity is a major health concern by itself, and adds to the morbidity and mortality caused by other important diseases in the cardiovascular and diabetes arena. Development of therapies for the treatment of obesity (drugs, devices, procedures) has been complex and difficult, and only recently have companies navigated through safety, efficacy and regulatory concerns to newly approved therapeutics. This panel will survey the current state of approaches to obesity, discuss the knowledge gained from the newly approved (and soon to be approved) drugs, and discuss the still unmet medical needs in this indication. Moderator:
Share this: Open innovation: Driver of future healthcare solutions? Wednesday, 8:00–9:00 am Level 3, Powell It's an accepted mantra that increased levels of openness are the route to innovation in the pharma, biotech and medtech sectors—and open innovation (OI) is starting to play a key role. No longer seen as an academic construct or something that only works in other industries, OI is now being embraced in healthcare in the form of diverse consortia and enhanced access to data, compounds and technologies. It is being used to develop enabling platforms, plus tackle difficult research questions and unmet medical needs. As with every new approach, however there are challenges—not least how to change mindsets, protect competitiveness while making sure intellectual property is an enabler, and keep the VCs on board. Join this workshop to hear about the latest developments in healthcare OI activities, how to meet challenges and establish projects, as well as the role of crowdfunding and the next potential developments. Moderator:
Share this: [ + ]Spinal cord injury: Investment opportunities and challenges in an area with unmet medical needs Spinal cord injury: Investment opportunities and challenges in an area with unmet medical needs Wednesday, 8:00–9:00 am Level 4, Hearst Spinal cord injuries (SCI) have a devastating impact on the health and well-being of individuals. Many would categorize SCI as one of the greatest survivable catastrophes experienced by a human being. The associated economic burden of SCI is substantial, not only due to direct healthcare costs, but also to high rates of physical morbidity, as well as premature mortality. Recent advances in SCI research, particularly around neuroregenerative strategies, combined with improved quality of care, have led to a more favorable environment in which to commercialize new therapies for the treatment of paralysis and the associated secondary complications. Come and listen to a panel of individuals from different aspects of the SCI commercialization continuum discuss the investment opportunities and challenges. This workshop will be followed by corporate presentations from companies currently developing therapeutics for SCI. Moderator:
Share this: Raising the evidence bar for biotech: What will FDA changes and increased payer scrutiny mean? Wednesday, 8:00–9:00 am Level 4, Mission I The science being the best it has ever been means that even more data can be collected on biotech candidates, some of which may be clinically relevant and some not. Nonetheless, FDA is asking for the data, and sponsors are having to decide what is feasible as part of product development, and what is negotiable as part of post approval study commitments. Further, with the possibility of biosimilars, FDA is reevaluating what is required of sponsors pre and post manufacturing changes. In addition the double-digit cost trend for biotech products is now getting the serious attention of payers: a perfect storm for biotech, or a perfect opportunity to show value perhaps? Moderator:
Share this: | 8:00 am–12:00 pm One-to-one Meetings ► |
|||
| 9:00 am–12:00 pm | Company Presentations ►
Private Biotech |
||||
| 12:00–1:40 pm |
Lunch Plenary The view from the street: Looking forward Wednesday, 12:00–1:40 pm Level 4, Cyril Magnin Ballroom The past several years have been challenging for biotech companies and investors in this sector on many fronts. As difficult as it has been, many companies continue to advance their programs and investors continue to support the sector, though with great caution. Looking forward, there are many questions. Is the IPO market opening up? How will investors value public companies? How are companies getting funding? How are investors generating a return on their investments? This panel of seasoned investors and analysts will have a candid and open discussion on what to expect in 2013/14. Moderator:
Share this: |
||||
| 1:45–5:00 pm | Company Presentations ►
Private Biotech |
1:30–5:00 pm One-to-one Meetings ► |
|||
| 5:00–6:00 pm |
Closing Reception
|
||||
